Carina Jørgensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carina Jørgensen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Bettina H Clausen
Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark , 5000 Odense , Denmark
1 shared publicationChristian Bernreuther
Department of Neuropathology, University Medical Center Hamburg-Eppendorf , 20246 Hamburg , Germany
1 shared publicationChristian Gerloff
Department of Neurology, University Medical Center Hamburg-Eppendorf , 20246 Hamburg , Germany
1 shared publication- Christina Kruuse
Department of Neurology, Copenhagen University Hospital-Herlev Gentofte and Department of Brain and Spinal Cord Injury, Copenhagen University Hospital-Rigshospitalet, Denmark (C.K.).
1 shared publication - Cornelius Faber
University of Munster
1 shared publication - Götz Thomalla
Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication
Latest Publications
- Open Access
- 2 March 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (2) , fcad090
A preclinical randomized controlled multi-centre trial of anti-interleukin-17A treatment for acute ischaemic stroke
Multiple consensus statements have called for preclinical randomized controlled trials to improve translation in stroke research. We investigated the efficacy of an interleukin-17A neutralizing antibody in a multi-centre preclinical randomized controlled trial using a murine ischaemia reperfusion stroke model. Twelve-week-old male C57BL/6 mice were subjected to 45 min of transient middle cerebral artery occlusion in four centres. Mice were randomly assigned (1:1) to receive either an anti-interleukin-17A (500 µg) or isotype antibody (500 µg) intravenously 1 h after reperfusion. The primary endpoint was infarct volume measured by magnetic resonance imaging three days after transient middle cerebral artery occlusion. Secondary analysis included mortality, neurological score, neutrophil infiltration and the impact of the gut microbiome on treatment effects. Out of 136 mice, 109 mice were included in the analysis of the primary endpoint. Mixed model analysis revealed that interleukin-17A neutralization significantly reduced infarct sizes (anti-interleukin-17A: 61.77 ± 31.04 mm3; IgG control: 75.66 ± 34.79 mm3; P = 0.01). Secondary outcome measures showed a decrease in mortality (hazard ratio = 3.43, 95% confidence interval = 1.157–10.18; P = 0.04) and neutrophil invasion into ischaemic cortices (anti-interleukin-17A: 7222 ± 6108 cells; IgG control: 28 153 ± 23 206 cells; P < 0.01). There was no difference in Bederson score. The analysis of the gut microbiome showed significant heterogeneity between centres (R = 0.78, P < 0.001, n = 40). Taken together, neutralization of interleukin-17A in a therapeutic time window resulted in a significant reduction of infarct sizes and mortality compared with isotype control. It suggests interleukin-17A neutralization as a potential therapeutic target in stroke.
- 2 March 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (2) , fcad090
Open AccessA preclinical randomized controlled multi-centre trial of anti-interleukin-17A treatment for acute ischaemic stroke
Multiple consensus statements have called for preclinical randomized controlled trials to improve translation in stroke research. We investigated the efficacy of an interleukin-17A neutralizing antibody in a multi-centre preclinical randomized controlled trial using a murine ischaemia reperfusion stroke model. Twelve-week-old male C57BL/6 mice were subjected to 45 min of transient middle cerebral artery occlusion in four centres. Mice were randomly assigned (1:1) to receive either an anti-interleukin-17A (500 µg) or isotype antibody (500 µg) intravenously 1 h after reperfusion. The primary endpoint was infarct volume measured by magnetic resonance imaging three days after transient middle cerebral artery occlusion. Secondary analysis included mortality, neurological score, neutrophil infiltration and the impact of the gut microbiome on treatment effects. Out of 136 mice, 109 mice were included in the analysis of the primary endpoint. Mixed model analysis revealed that interleukin-17A neutralization significantly reduced infarct sizes (anti-interleukin-17A: 61.77 ± 31.04 mm3; IgG control: 75.66 ± 34.79 mm3; P = 0.01). Secondary outcome measures showed a decrease in mortality (hazard ratio = 3.43, 95% confidence interval = 1.157–10.18; P = 0.04) and neutrophil invasion into ischaemic cortices (anti-interleukin-17A: 7222 ± 6108 cells; IgG control: 28 153 ± 23 206 cells; P < 0.01). There was no difference in Bederson score. The analysis of the gut microbiome showed significant heterogeneity between centres (R = 0.78, P < 0.001, n = 40). Taken together, neutralization of interleukin-17A in a therapeutic time window resulted in a significant reduction of infarct sizes and mortality compared with isotype control. It suggests interleukin-17A neutralization as a potential therapeutic target in stroke.
- 1 December 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 359 (1-2) , 266-274
Phosphodiesterase4D (PDE4D) — A risk factor for atrial fibrillation and stroke?
- 1 December 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 359 (1-2) , 266-274
Phosphodiesterase4D (PDE4D) — A risk factor for atrial fibrillation and stroke?